Efficacy and Safety of Bictegravir-Based Regimen in Pregnant Women Living with HIV: A Case Report

Bictegravir (BIC) is included in international guidelines as the first line of therapy for patients living with Human Immunodeficiency Virus (HIV), either as initial therapy or as a replacement for patients with prior antiretroviral therapy (ART). Due to limited efficacy and safety data, BIC is curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsulami, Shaimaa, Alotaibi, Sultan N., Damfu, Nader, Aljefri, Doaa M., Altayib, Hadeel Ahmed, Alharbi, Maher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772963/
https://www.ncbi.nlm.nih.gov/pubmed/36529886
http://dx.doi.org/10.1177/23259582221146110
Descripción
Sumario:Bictegravir (BIC) is included in international guidelines as the first line of therapy for patients living with Human Immunodeficiency Virus (HIV), either as initial therapy or as a replacement for patients with prior antiretroviral therapy (ART). Due to limited efficacy and safety data, BIC is currently not recommended during pregnancy. Data on the safety and efficacy of BIC during pregnancy were unavailable at the time of drug approval. In our case, BIC/TAF/FTC was effective in suppressing viral load (VL) in pregnancy, and there were no reported safety issues for the mother or the baby.

Ejemplares similares